EWING, N.J., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc., (OTCBB:CLPM), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will report financial results for the third quarter ended September 30, 2013, on Tuesday, November 12, 2013. Celator's management team will host a conference call and live audio webcast at 4:30 p.m. EST on Tuesday, November 12, 2013, to discuss the quarterly results and provide a business update.
To access the conference call, please dial 1-877-303-6316 (domestic) or 1-650-521-5176 (international) and refer to conference ID 98015618. The live webcast of the call will be available on the Investors section of the Company's website, www.celatorpharma.com. An archived webcast will be available on the Company's website approximately two hours after the event.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:floxuridine), and hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will" "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our expectations regarding our development plans for and the potential efficacy and therapeutic potential of our drug candidates and other matters that could affect the availability or commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2012 and other filings by the company with the U.S. Securities and Exchange Commission.
CONTACT: Media: Mike Beyer, Sam Brown, Inc. 773-463-4211, firstname.lastname@example.org Investors: Beth DelGiacco, Stern Investor Relations, Inc. (212) 362-1200, email@example.comSource:Celator Pharmaceuticals. Inc.